Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans

Neuropharmacology

Volumn 59, Issue 4-5, 2010, Pages 358-365

  Keowkase, Roongpetch ^a   Aboukhatwa, Marwa ^a   Luo, Yuan ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; C. elegans; Fluoxetine; Selective serotonin reuptake inhibitor

Indexed keywords

AMYLOID BETA PROTEIN; CELL PROTEIN; CITALOPRAM; FLUOXETINE; INSULIN; PAROXETINE; PROTEIN TPH 1; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CAENORHABDITIS ELEGANS; CELL PROTECTION; CONTROLLED STUDY; HEAT STRESS; HEAT TOLERANCE; LIFE EXTENSION; NEUROBLASTOMA CELL; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEOTOXICITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOXICITY; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELLS, CULTURED; FLUOXETINE; HUMANS; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77955923792     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.04.008     Document Type: Article

References (66)

1. Aboukhatwa M., Dosanjh L., Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol. Neurodegener. 2010, 5:10.
2. Altman H.J., Stone W.S., Ogren S.O. Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval. Behav. Neural Biol. 1987, 48(1):49-62.
3. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368(9533):387-403.
4. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974, 77(1):71-94.
5. Carrasco J.L., Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int. J. Clin. Pract. 2005, 59(12):1428-1434.
6. Chavant F., Deguil J., Pain S., Ingrand I., Milin S., Fauconneau B., Perault M.C., Lafay-Chebassier C. Imipramine, in part through TNF-{alpha} inhibition, prevents cognitive decline and A{beta} accumulation in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther 2009.
7. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y.D., Ma T., Thompson R.C., Zhao Y., Smith L., Gasparini L., Luo Z., Xu H., Liao F.F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(10):3907-3912.
8. Cohen E., Bieschke J., Perciavalle R.M., Kelly J.W., Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006, 313(5793):1604-1610.
9. Cohen E., Dillin A. The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat. Rev. Neurosci. 2008, 9(10):759-767.
10. Cole G.M., Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 2007, 42(1-2):10-21.
11. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 2007, 4(2):147-152.
12. Craft S., Asthana S., Cook D.G., Baker L.D., Cherrier M., Purganan K., Wait C., Petrova A., Latendresse S., Watson G.S., Newcomer J.W., Schellenberg G.D., Krohn A.J. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003, 28(6):809-822.
13. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 2004, 351(1):56-67.
14. Danion J.M. Encephale 1993, 19(Spec No 2):417-422.
15. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., Drew M., Craig D.A., Guiard B.P., Guilloux J.P., Artymyshyn R.P., Gardier A.M., Gerald C., Antonijevic I.A., Leonardo E.D., Hen R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62(4):479-493.
16. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(6):1971-1976.
17. Dempsey C.M., Mackenzie S.M., Gargus A., Blanco G., Sze J.Y. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. Genetics 2005, 169(3):1425-1436.
18. Duman R.S. Novel therapeutic approaches beyond the serotonin receptor. Biol. Psychiatry 1998, 44(5):324-335.
19. Faber P.W., Alter J.R., MacDonald M.E., Hart A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(1):179-184.
20. Finkel S.I., Mintzer J.E., Dysken M., Krishnan K.R., Burt T., McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int. J. Geriatr. Psychiatry 2004, 19(1):9-18.
21. Freude S., Hettich M.M., Schumann C., Stohr O., Koch L., Kohler C., Udelhoven M., Leeser U., Muller M., Kubota N., Kadowaki T., Krone W., Schroder H., Bruning J.C., Schubert M. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. Faseb J. 2009, 23(10):3315-3324.
22. Geerlings M.I., Schoevers R.A., Beekman A.T., Jonker C., Deeg D.J., Schmand B., Ader H.J., Bouter L.M., Van Tilburg W. Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands. Br. J. Psychiatry 2000, 176:568-575.
23. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
24. Jacobs B.L., Praag H., Gage F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry 2000, 5(3):262-269.
25. Kaletta T., Hengartner M.O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov. 2006, 5(5):387-398.
26. Kuningas M., Magi R., Westendorp R.G., Slagboom P.E., Remm M., van Heemst D. Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur. J. Hum. Genet. 2007, 15(3):294-301.
27. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24(45):10191-10200.
28. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27(4):796-807.
29. Lai M.K., Tsang S.W., Francis P.T., Keene J., Hope T., Esiri M.M., Spence I., Chen C.P. Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 2002, 13(9):1175-1178.
30. Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., Blakely R.D., Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 2003, 86(1):165-172.
31. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(11):6448-6453.
32. Lee H.B., Lyketsos C.G. Depression in Alzheimer's disease: heterogeneity and related issues. Biol. Psychiatry 2003, 54(3):353-362.
33. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(20):9368-9372.
34. Link C.D. Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech. Ageing Dev. 2001, 122(14):1639-1649.
35. Link C.D. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp. Gerontol. 2006, 41(10):1007-1013.
36. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20(24):9104-9110.
37. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46(6):860-866.
38. Mowla A., Mosavinasab M., Haghshenas H., Haghighi A.B. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 2007, 27(5):484-487.
39. Mowla A., Mosavinasab M., Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol. 2007, 27(1):67-70.
40. Mukhopadhyay A., Oh S.W., Tissenbaum H.A. Worming pathways to and from DAF-16/FOXO. Exp. Gerontol. 2006, 41(10):928-934.
41. Murakami H., Murakami S. Serotonin receptors antagonistically modulate Caenorhabditis elegans longevity. Aging Cell 2007, 6(4):483-488.
42. Murphy C.T. The search for DAF-16/FOXO transcriptional targets: approaches and discoveries. Exp. Gerontol. 2006, 41(10):910-921.
43. Nass R., Hall D.H., Miller D.M., Blakely R.D. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(5):3264-3269.
44. Nelson R.L., Guo Z., Halagappa V.M., Pearson M., Gray A.J., Matsuoka Y., Brown M., Martin B., Iyun T., Maudsley S., Clark R.F., Mattson M.P. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol. 2007, 205(1):166-176.
45. Nyth A.L., Gottfries C.G. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br. J. Psychiatry 1990, 157:894-901.
46. Nyth A.L., Gottfries C.G., Lyby K., Smedegaard-Andersen L., Gylding-Sabroe J., Kristensen M., Refsum H.E., Ofsti E., Eriksson S., Syversen S. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr. Scand. 1992, 86(2):138-145.
47. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 2001, 50(5):345-350.
48. Palvimaki E.P., Kuoppamaki M., Syvalahti E., Hietala J. Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain. Int. J. Neuropsychopharmacol. 1999, 2(2):95-99.
49. Pollock B.G., Rosen J., Mulsant B.H. Antipsychotics and selective serotonin reuptake inhibitors for the treatment of behavioral disturbances in dementia of the Alzheimer type. Consultant Pharm. 1999, 11:1251-1258.
50. Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Booker L., Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 2008, 148(5):379-397.
51. Resende R., Ferreiro E., Pereira C., Resende de Oliveira C. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008, 155(3):725-737.
52. Rozzini L., Chilovi B.V., Conti M., Bertoletti E., Zanetti M., Trabucchi M., Padovani A. Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. Int. Psychogeriatr. 2010, 22(1):114-119.
53. Schaffitzel E., Hertweck M. Recent aging research in Caenorhabditis elegans. Exp. Gerontol. 2006, 41(6):557-563.
54. Schmitt J.A., Wingen M., Ramaekers J.G., Evers E.A., Riedel W.J. Serotonin and human cognitive performance. Curr. Pharm. Des. 2006, 12(20):2473-2486.
55. Shah S., Reichman W.E. Treatment of Alzheimer's disease across the spectrum of severity. Clin. Interv. Aging 2006, 1(2):131-142.
56. Thompson S., Herrmann N., Rapoport M.J., Lanctot K.L. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can. J. Psychiatry 2007, 52(4):248-255.
57. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282(46):33305-33312.
58. van Marum R.J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. 2008, 22(3):265-274.
59. Vijg J., Campisi J. Puzzles, promises and a cure for ageing. Nature 2008, 454(7208):1065-1071.
60. Visser P.J., Verhey F.R., Ponds R.W., Kester A., Jolles J. Distinction between preclinical Alzheimer's disease and depression. J. Am. Geriatr. Soc. 2000, 48(5):479-484.
61. Vythilingam M., Vermetten E., Anderson G.M., Luckenbaugh D., Anderson E.R., Snow J., Staib L.H., Charney D.S., Bremner J.D. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol. Psychiatry 2004, 56(2):101-112.
62. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 2005, 13(11):950-958.
63. Wilde M.I., Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 1998, 13(5 Pt 1):543-561.
64. Wu Y., Wu Z., Butko P., Christen Y., Lambert M.P., Klein W.L., Link C.D., Luo Y. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 2006, 26(50):13102-13113.
65. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. Faseb J. 2008, 22(1):246-260.
66. Zhao W.Q., Lacor P.N., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J. Biol. Chem. 2009, 284(28):18742-18753.